A revolutionary step in diabetes management
The ACME Laboratories Ltd., one of Bangladesh’s leading pharmaceutical companies, has taken a historic initiative to address the challenges of diabetes management and create a milestone in treating type-2 diabetes in the country.
On Wednesday, December 4, 2024, a grand event was held at the prestigious Samson H. Chowdhury Centre, Dhaka Club, to present the success of the Emlino Exemplify Trial, conducted for the first time in Bangladesh among Bangladeshi diabetes patients. The event also honoured the doctors involved in this groundbreaking initiative with respect and gratitude.
Renowned diabetes specialists from across the country attended the program. Experts highlighted that Emlino not only helps manage blood sugar levels in diabetes patients but also supports weight and blood pressure management, reducing the risk of heart disease and protecting kidney health.
The Chief Guest graced the event, National Professor AK Azad Khan, President of the Bangladesh Diabetic Association, and Special Guest, Professor Dr Faruque Pathan, Director of BIRDEM Academy. The trial’s lead researcher, Dr Mirza Sharifuzzaman, and other distinguished guests, such as Professor Dr Md. Hafizur Rahman, Professor Dr Md. Abdul Jalil Ansari, and Professor Dr Ajit Kumar Paul, also attended the occasion.
The esteemed expert panel, which included Professor Dr Feroz Amin, Dr Shahjada Selim, Dr Faria Afsana, and Dr M. Saifuddin, among many other prominent physicians, contributed to the event’s success.
The ACME Laboratories Ltd. has long been committed to delivering effective and timely solutions for diabetes management. The Emlino Exemplify Trial is a testament to their continuous efforts in this mission.
Source: The Business Standard | 7 December 2024
